| abstract |
Use of low molecular weight heparin, with an average molecular weight of about 3000 to about 10,000, of the enoxaparin, nardroparin, dalteparin, certroparin, parnaparin, reviparin, ardeparin / RD, heparin / RDH or tinzaparin series, or a mixture thereof , for the preparation of drugs for the prophylaxis and treatment of diseases, to which an increased activity of at least one of the collagenase matrix metalloproteinases of neutrophils, aggrecanase, hADAMTS1 and gelatinase A, of the series of osteoarthritis, spondylosis, loss, contributes of cartilage after joint trauma or prolonged joint immobilization that follows lesions of the meniscus or kneecap or ligament tears, or a connective tissue disease, such as collagen, disorders during wound healing or perverse diseases . |